Table 3.

Multivariable Analyses of Covariables Associated with Intracranial Progression-Free Survival

Factors	HR	95% CI	P-value
Group
Targeted-radiotherapy vs Radiotherapy-targeted	0.160	0.073–0.352	< 0.001
Time from the first diagnosis to BM (m)
≥ 29 vs < 29	0.961	0.495–1.866	0.906
Number of BM
1–3 vs > 3	1.805	0.949–3.433	0.072
Molecular subtype (n)
Luminal B (HER2+) vs HER2 overexpression	0.812	0.428–1.539	0.523
Treatment of Primary breast disease
Primary surgical treatment
Yes vs No	0.808	0.394–0.656	0.560
Treatment after BM Chemotherapy
Yes vs No	0.872	0.320–2.375	0.789

Abbreviations: HR, hazard ratio; CI, confidence interval; iPFS, intracranial progression-free survival; BM, brain metastasis; HER2, human epidermal growth factor receptor 2.